- Home
- LFCR
as 09-30-2025 2:32pm EST
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
Upcoming Earnings Alert:
Get ready for potential market movements as Lifecore Biomedical Inc. LFCR prepares to release earnings report on 03 Oct 2025.
| Founded: | 1986 | Country: | United States |
| Employees: | N/A | City: | CHASKA |
| Market Cap: | 288.0M | IPO Year: | N/A |
| Target Price: | $8.00 | AVG Volume (30 days): | 173.0K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.33 - $8.85 | Next Earning Date: | 10-03-2025 |
| Revenue: | $128,867,000 | Revenue Growth: | 0.47% |
| Revenue Growth (this year): | 4.71% | Revenue Growth (next year): | 10.98% |
Latest Lifecore Biomedical Inc. News
LFCR Breaking Stock News: Dive into LFCR Ticker-Specific Updates for Smart Investing
Zacks
18 days ago
Lifecore Biomedical (LFCR) Soars 10.8%: Is Further Upside Left in the Stock?
GlobeNewswire
a month ago
Lifecore Biomedical to Participate at 24th Annual Contract Pharma Contracting and Outsourcing Conference
MT Newswires
3 months ago
Lifecore Biomedical Signs 10-Year Manufacturing, Supply Deal With Ophthalmic Therapy Customer
GlobeNewswire
3 months ago
Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer
MT Newswires
4 months ago
Lifecore Biomedical Receives Remaining $10 Million for Sale of Isolator Filler Ahead of Schedule
GlobeNewswire
4 months ago
Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale
Simply Wall St.
4 months ago
Lifecore Biomedical (NASDAQ:LFCR) shareholders have endured a 37% loss from investing in the stock five years ago
GlobeNewswire
4 months ago
Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer
Compare LFCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LFCR Lifecore Biomedical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.